US 11,794,013 B2
Treatment of inflammation by selective DMV cholinergic neuron stimulation
Adam M. Kressel, Plainview, NY (US); Valentin A. Pavlov, Bayside, NY (US); Sangeeta S. Chavan, Syosset, NY (US); and Kevin J. Tracey, Old Greenwich, CT (US)
Assigned to The Feinstein Institutes for Medical Research, Manhasset, NY (US)
Filed by The Feinstein Institutes for Medical Research, Manhasset, NY (US)
Filed on Feb. 24, 2021, as Appl. No. 17/184,197.
Application 17/184,197 is a continuation of application No. 16/272,295, filed on Feb. 11, 2019, granted, now 10,933,240.
Claims priority of provisional application 62/629,149, filed on Feb. 12, 2018.
Prior Publication US 2021/0196955 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61N 1/04 (2006.01)
CPC A61N 1/36053 (2013.01) [A61N 1/0412 (2013.01); A61N 1/0536 (2013.01); A61N 1/3615 (2013.01); A61N 1/0504 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method of suppressing or ameliorating inflammation in a subject comprising selectively electrically stimulating cholinergic neuronal activity in a vagal nerve of the subject, wherein no other vagal nerve activity is selectively electrically stimulated, and wherein the stimulated cholinergic neuronal activity is effected using microelectrodes placed externally to the subject's central nervous system, and wherein the stimulated cholinergic neuronal activity is effective to induce splenic nerve activity suppression of TNF release so as to suppress or ameliorate inflammation in a subject.